You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameArsenic trioxide
Accession NumberDB01169  (APRD00171)
TypeSmall Molecule
GroupsApproved, Investigational
DescriptionArsenic trioxide is a chemotheraputic agent of idiopathic function used to treat leukemia that is unresponsive to first line agents. It is suspected that arsenic trisulfide induces cancer cells to undergo apoptosis. Due to the toxic nature of arsenic, this drug carries significant health risks. The enzyme thioredoxin reductase has recently been identified as a target for arsenic trioxide.
Structure
Thumb
Synonyms
Acide Arsenieux
Anhydride Arsenieux
Arseneous anhydride
Arseneous oxide
Arseni Trioxydum
Arsenic Blanc
Arsenic oxide
Arsenic Oxidearsenous Trioxide
Arsenic sesquioxide
Arsenic(III) oxide
Arsenicum album
Arsenigen Saure
Arsenious Acid
Arsenious Acid Anhydride
Arsenious Trioxide
Arsenolite
Arsentrioxide
Diarsenic trioxide
Oxyde Arsenieux
Tetraarsenic hexaoxide
White arsenic
External Identifiers Not Available
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
TrisenoxSolution1 mgIntravenousLundbeck Canada Inc2013-09-09Not applicableCanada
TrisenoxInjection, solution1 mg/mLIntravenousCephalon, Inc.2000-10-15Not applicableUs
Approved Generic Prescription ProductsNot Available
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International BrandsNot Available
Brand mixturesNot Available
SaltsNot Available
Categories
UNIIS7V92P67HO
CAS number1327-53-3
WeightAverage: 197.84
Monoisotopic: 197.827934
Chemical FormulaAs2O3
InChI KeyMOQADKPFYVWPSE-UHFFFAOYSA-N
InChI
InChI=1S/As2O3/c3-1-2(4)5
IUPAC Name
(arsoarsoroso)arsane
SMILES
O=[As][As](=O)=O
Pharmacology
IndicationFor induction of remission and consolidation in patients with acute promyelocytic leukemia (APL), and whose APL is characterized by the presence of the t(15;17) translocation or PML/RAR-alpha gene expression
Structured Indications
PharmacodynamicsArsenic Trioxide is indicated for induction of remission and consolidation in patients with acute promyelocytic leukemia (APL) who are refractory to, or have relapsed from, retinoid and anthracycline chemotherapy.
Mechanism of actionThe mechanism of action of Arsenic Trioxide is not completely understood. Arsenic trioxide causes morphological changes and DNA fragmentation characteristic of apoptosis in NB4 human promyelocytic leukemia cells in vitro. Arsenic trioxide also causes damage or degradation of the fusion protein PML/RAR-alpha. It is suspected that arsenic trioxide induces cancer cells to undergo apoptosis.
TargetKindPharmacological actionActionsOrganismUniProt ID
Inhibitor of nuclear factor kappa-B kinase subunit betaProteinyes
inducer
HumanO14920 details
Thioredoxin reductase 1, cytoplasmicProteinyes
inhibitor
HumanQ16881 details
Transcription factor AP-1Proteinyes
inducer
HumanP05412 details
G1/S-specific cyclin-D1Proteinyes
antagonist
HumanP24385 details
Mitogen-activated protein kinase 3Proteinyes
inducer
HumanP27361 details
Mitogen-activated protein kinase 1Proteinyes
inducer
HumanP28482 details
RAC-alpha serine/threonine-protein kinaseProteinunknown
inducer
HumanP31749 details
Related Articles
AbsorptionNot Available
Volume of distributionNot Available
Protein binding75% bound
Metabolism

The metabolism of arsenic trioxide involves reduction of pentavalent arsenic to trivalent arsenic by arsenate reductase and methylation of trivalent arsenic to monomethylarsonic acid and monomethylarsonic acid to dimethylarsinic acid by methyltransferases. The main site of methylation reactions appears to be the liver. Arsenic is stored mainly in liver, kidney, heart, lung, hair and nails.

Route of eliminationTrivalent arsenic is mostly methylated in humans and excreted in urine.
Half lifeNot Available
ClearanceNot Available
ToxicitySymptoms of overdose include convulsions, muscle weakness and confusion.
Affected organisms
  • Humans and other mammals
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
Interactions
Drug Interactions
DrugInteractionDrug group
AcarboseThe therapeutic efficacy of Acarbose can be decreased when used in combination with Arsenic trioxide.Approved, Investigational
AcebutololThe risk or severity of adverse effects can be increased when Acebutolol is combined with Arsenic trioxide.Approved
AcetaminophenThe serum concentration of Arsenic trioxide can be increased when it is combined with Acetaminophen.Approved
AcetazolamideThe risk or severity of adverse effects can be increased when Arsenic trioxide is combined with Acetazolamide.Approved, Vet Approved
AcetohexamideThe therapeutic efficacy of Acetohexamide can be decreased when used in combination with Arsenic trioxide.Withdrawn
AcetyldigitoxinAcetyldigitoxin may decrease the cardiotoxic activities of Arsenic trioxide.Approved
AfatinibThe serum concentration of Arsenic trioxide can be increased when it is combined with Afatinib.Approved
AicarThe therapeutic efficacy of Aicar can be decreased when used in combination with Arsenic trioxide.Experimental
AlbendazoleThe serum concentration of Arsenic trioxide can be increased when it is combined with Albendazole.Approved, Vet Approved
AldesleukinThe risk or severity of adverse effects can be increased when Aldesleukin is combined with Arsenic trioxide.Approved
AldosteroneThe serum concentration of Arsenic trioxide can be decreased when it is combined with Aldosterone.Experimental
AlectinibThe serum concentration of Arsenic trioxide can be increased when it is combined with Alectinib.Approved
AlfentanilThe serum concentration of Arsenic trioxide can be increased when it is combined with Alfentanil.Approved, Illicit
AlfuzosinAlfuzosin may increase the QTc-prolonging activities of Arsenic trioxide.Approved, Investigational
AliskirenThe risk or severity of adverse effects can be increased when Aliskiren is combined with Arsenic trioxide.Approved, Investigational
AlogliptinThe therapeutic efficacy of Alogliptin can be decreased when used in combination with Arsenic trioxide.Approved
AmantadineAmantadine may increase the QTc-prolonging activities of Arsenic trioxide.Approved
AmifostineThe risk or severity of adverse effects can be increased when Amifostine is combined with Arsenic trioxide.Approved, Investigational
AmilorideThe risk or severity of adverse effects can be increased when Amiloride is combined with Arsenic trioxide.Approved
Aminohippuric acidThe serum concentration of Arsenic trioxide can be increased when it is combined with Aminohippuric acid.Approved
AmiodaroneAmiodarone may increase the QTc-prolonging activities of Arsenic trioxide.Approved, Investigational
AmitriptylineAmitriptyline may increase the QTc-prolonging activities of Arsenic trioxide.Approved
AmlodipineThe serum concentration of Arsenic trioxide can be increased when it is combined with Amlodipine.Approved
AmobarbitalAmobarbital may increase the hypotensive activities of Arsenic trioxide.Approved, Illicit
AmoxapineAmoxapine may increase the QTc-prolonging activities of Arsenic trioxide.Approved
Amphotericin BThe risk or severity of adverse effects can be increased when Amphotericin B is combined with Arsenic trioxide.Approved, Investigational
AmprenavirThe serum concentration of Arsenic trioxide can be decreased when it is combined with Amprenavir.Approved
AmsacrineThe serum concentration of Arsenic trioxide can be increased when it is combined with Amsacrine.Approved
Amyl NitriteThe risk or severity of adverse effects can be increased when Amyl Nitrite is combined with Arsenic trioxide.Approved
AnagrelideAnagrelide may increase the QTc-prolonging activities of Arsenic trioxide.Approved
AnvirzelAnvirzel may decrease the cardiotoxic activities of Arsenic trioxide.Investigational
ApomorphineApomorphine may increase the QTc-prolonging activities of Arsenic trioxide.Approved, Investigational
ApraclonidineThe risk or severity of adverse effects can be increased when Apraclonidine is combined with Arsenic trioxide.Approved
ArformoterolArformoterol may increase the QTc-prolonging activities of Arsenic trioxide.Approved, Investigational
AripiprazoleAripiprazole may increase the hypotensive activities of Arsenic trioxide.Approved, Investigational
ArotinololThe risk or severity of adverse effects can be increased when Arotinolol is combined with Arsenic trioxide.Approved
ArtemetherArsenic trioxide may increase the QTc-prolonging activities of Artemether.Approved
AsenapineArsenic trioxide may increase the QTc-prolonging activities of Asenapine.Approved
AstemizoleThe serum concentration of Arsenic trioxide can be increased when it is combined with Astemizole.Approved, Withdrawn
AtazanavirAtazanavir may increase the QTc-prolonging activities of Arsenic trioxide.Approved, Investigational
AtenololThe serum concentration of Arsenic trioxide can be increased when it is combined with Atenolol.Approved
AtomoxetineAtomoxetine may increase the QTc-prolonging activities of Arsenic trioxide.Approved
AtorvastatinThe serum concentration of Arsenic trioxide can be increased when it is combined with Atorvastatin.Approved
AzelastineThe serum concentration of Arsenic trioxide can be increased when it is combined with Azelastine.Approved
Azilsartan medoxomilThe risk or severity of adverse effects can be increased when Azilsartan medoxomil is combined with Arsenic trioxide.Approved
AzithromycinAzithromycin may increase the QTc-prolonging activities of Arsenic trioxide.Approved
BalaglitazoneThe therapeutic efficacy of Balaglitazone can be decreased when used in combination with Arsenic trioxide.Investigational
BarbexacloneBarbexaclone may increase the hypotensive activities of Arsenic trioxide.Experimental
BarbitalBarbital may increase the hypotensive activities of Arsenic trioxide.Illicit
BarnidipineThe risk or severity of adverse effects can be increased when Arsenic trioxide is combined with Barnidipine.Approved
BcgThe therapeutic efficacy of Bcg can be decreased when used in combination with Arsenic trioxide.Investigational
BedaquilineBedaquiline may increase the QTc-prolonging activities of Arsenic trioxide.Approved
BenazeprilThe risk or severity of adverse effects can be increased when Benazepril is combined with Arsenic trioxide.Approved, Investigational
BendroflumethiazideThe risk or severity of adverse effects can be increased when Bendroflumethiazide is combined with Arsenic trioxide.Approved
BenzocaineThe serum concentration of Arsenic trioxide can be increased when it is combined with Benzocaine.Approved
BepridilThe serum concentration of Arsenic trioxide can be increased when it is combined with Bepridil.Approved, Withdrawn
BetaxololThe risk or severity of adverse effects can be increased when Betaxolol is combined with Arsenic trioxide.Approved
BevacizumabBevacizumab may increase the cardiotoxic activities of Arsenic trioxide.Approved, Investigational
BiperidenThe serum concentration of Arsenic trioxide can be increased when it is combined with Biperiden.Approved
BisoprololThe risk or severity of adverse effects can be increased when Bisoprolol is combined with Arsenic trioxide.Approved
BortezomibBortezomib may increase the QTc-prolonging activities of Arsenic trioxide.Approved, Investigational
BosutinibThe serum concentration of Arsenic trioxide can be increased when it is combined with Bosutinib.Approved
BretyliumThe risk or severity of adverse effects can be increased when Bretylium is combined with Arsenic trioxide.Approved
BrimonidineThe risk or severity of adverse effects can be increased when Brimonidine is combined with Arsenic trioxide.Approved
BromocriptineThe serum concentration of Arsenic trioxide can be increased when it is combined with Bromocriptine.Approved, Investigational
BuforminThe therapeutic efficacy of Buformin can be decreased when used in combination with Arsenic trioxide.Withdrawn
BumetanideThe risk or severity of adverse effects can be increased when Bumetanide is combined with Arsenic trioxide.Approved
BupivacaineThe risk or severity of adverse effects can be increased when Arsenic trioxide is combined with Bupivacaine.Approved, Investigational
BuprenorphineThe serum concentration of Arsenic trioxide can be increased when it is combined with Buprenorphine.Approved, Illicit, Investigational, Vet Approved
BuserelinBuserelin may increase the QTc-prolonging activities of Arsenic trioxide.Approved
BuspironeThe serum concentration of Arsenic trioxide can be increased when it is combined with Buspirone.Approved, Investigational
CabazitaxelThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Arsenic trioxide.Approved
CaffeineThe serum concentration of Arsenic trioxide can be increased when it is combined with Caffeine.Approved
CanagliflozinThe risk or severity of adverse effects can be increased when Canagliflozin is combined with Arsenic trioxide.Approved
CandesartanThe serum concentration of Arsenic trioxide can be increased when it is combined with Candesartan.Approved
CaptoprilThe serum concentration of Arsenic trioxide can be increased when it is combined with Captopril.Approved
CarbamazepineThe serum concentration of Arsenic trioxide can be decreased when it is combined with Carbamazepine.Approved, Investigational
CarbetocinThe risk or severity of adverse effects can be increased when Arsenic trioxide is combined with Carbetocin.Approved
CarteololThe risk or severity of adverse effects can be increased when Carteolol is combined with Arsenic trioxide.Approved
CarvedilolThe serum concentration of Arsenic trioxide can be increased when it is combined with Carvedilol.Approved, Investigational
CaspofunginThe serum concentration of Arsenic trioxide can be increased when it is combined with Caspofungin.Approved
CastanospermineThe therapeutic efficacy of Castanospermine can be decreased when used in combination with Arsenic trioxide.Experimental
CeritinibCeritinib may increase the QTc-prolonging activities of Arsenic trioxide.Approved
ChloroquineChloroquine may increase the QTc-prolonging activities of Arsenic trioxide.Approved, Vet Approved
ChlorothiazideThe risk or severity of adverse effects can be increased when Chlorothiazide is combined with Arsenic trioxide.Approved, Vet Approved
ChlorpromazineChlorpromazine may increase the QTc-prolonging activities of Arsenic trioxide.Approved, Vet Approved
ChlorpropamideThe serum concentration of Arsenic trioxide can be increased when it is combined with Chlorpropamide.Approved
ChlorprothixeneThe serum concentration of Arsenic trioxide can be increased when it is combined with Chlorprothixene.Approved, Withdrawn
ChlorthalidoneThe risk or severity of adverse effects can be increased when Chlorthalidone is combined with Arsenic trioxide.Approved
CholesterolThe serum concentration of Arsenic trioxide can be increased when it is combined with Cholesterol.Experimental
Cholic AcidThe serum concentration of Arsenic trioxide can be decreased when it is combined with Cholic Acid.Approved
CiglitazoneThe therapeutic efficacy of Ciglitazone can be decreased when used in combination with Arsenic trioxide.Experimental
CilazaprilThe serum concentration of Arsenic trioxide can be increased when it is combined with Cilazapril.Approved
CilnidipineThe risk or severity of adverse effects can be increased when Arsenic trioxide is combined with Cilnidipine.Approved
CimetidineThe serum concentration of Arsenic trioxide can be decreased when it is combined with Cimetidine.Approved
CiprofloxacinCiprofloxacin may increase the QTc-prolonging activities of Arsenic trioxide.Approved, Investigational
CisaprideCisapride may increase the QTc-prolonging activities of Arsenic trioxide.Approved, Investigational, Withdrawn
CitalopramCitalopram may increase the QTc-prolonging activities of Arsenic trioxide.Approved
ClarithromycinClarithromycin may increase the QTc-prolonging activities of Arsenic trioxide.Approved
ClevidipineThe risk or severity of adverse effects can be increased when Clevidipine is combined with Arsenic trioxide.Approved
ClofarabineThe risk or severity of adverse effects can be increased when Arsenic trioxide is combined with Clofarabine.Approved, Investigational
ClofazimineThe serum concentration of Arsenic trioxide can be increased when it is combined with Clofazimine.Approved, Investigational
ClomipramineClomipramine may increase the QTc-prolonging activities of Arsenic trioxide.Approved, Vet Approved
ClonidineThe risk or severity of adverse effects can be increased when Clonidine is combined with Arsenic trioxide.Approved
ClotrimazoleThe serum concentration of Arsenic trioxide can be decreased when it is combined with Clotrimazole.Approved, Vet Approved
ClozapineThe risk or severity of adverse effects can be increased when Arsenic trioxide is combined with Clozapine.Approved
CobicistatThe serum concentration of Arsenic trioxide can be increased when it is combined with Cobicistat.Approved
ColchicineThe serum concentration of Arsenic trioxide can be increased when it is combined with Colchicine.Approved
ColforsinThe serum concentration of Arsenic trioxide can be increased when it is combined with Colforsin.Experimental
ConivaptanThe risk or severity of adverse effects can be increased when Arsenic trioxide is combined with Conivaptan.Approved, Investigational
CrizotinibCrizotinib may increase the QTc-prolonging activities of Arsenic trioxide.Approved
CyclophosphamideCyclophosphamide may increase the cardiotoxic activities of Arsenic trioxide.Approved, Investigational
CyclosporineThe serum concentration of Arsenic trioxide can be decreased when it is combined with Cyclosporine.Approved, Investigational, Vet Approved
DabrafenibDabrafenib may increase the QTc-prolonging activities of Arsenic trioxide.Approved
DaclatasvirThe serum concentration of Arsenic trioxide can be increased when it is combined with Daclatasvir.Approved
DactinomycinThe serum concentration of Arsenic trioxide can be increased when it is combined with Dactinomycin.Approved
DapagliflozinThe risk or severity of adverse effects can be increased when Dapagliflozin is combined with Arsenic trioxide.Approved
DasatinibDasatinib may increase the QTc-prolonging activities of Arsenic trioxide.Approved, Investigational
DaunorubicinThe serum concentration of Arsenic trioxide can be decreased when it is combined with Daunorubicin.Approved
DegarelixDegarelix may increase the QTc-prolonging activities of Arsenic trioxide.Approved
DeoxyspergualinThe therapeutic efficacy of Deoxyspergualin can be decreased when used in combination with Arsenic trioxide.Investigational
DesfluraneDesflurane may increase the QTc-prolonging activities of Arsenic trioxide.Approved
DesipramineDesipramine may increase the QTc-prolonging activities of Arsenic trioxide.Approved
DeslanosideDeslanoside may decrease the cardiotoxic activities of Arsenic trioxide.Approved
DesloratadineThe serum concentration of Arsenic trioxide can be increased when it is combined with Desloratadine.Approved, Investigational
DexamethasoneThe serum concentration of Arsenic trioxide can be decreased when it is combined with Dexamethasone.Approved, Investigational, Vet Approved
DexmedetomidineThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Arsenic trioxide.Approved, Vet Approved
DextromethorphanThe serum concentration of Arsenic trioxide can be increased when it is combined with Dextromethorphan.Approved
DiclofenacThe serum concentration of Arsenic trioxide can be increased when it is combined with Diclofenac.Approved, Vet Approved
DiclofenamideThe risk or severity of adverse effects can be increased when Diclofenamide is combined with Arsenic trioxide.Approved
DigitoxinDigitoxin may decrease the cardiotoxic activities of Arsenic trioxide.Approved
DigoxinDigoxin may decrease the cardiotoxic activities of Arsenic trioxide.Approved
DihydroergotamineThe serum concentration of Arsenic trioxide can be increased when it is combined with Dihydroergotamine.Approved
DiltiazemThe serum concentration of Arsenic trioxide can be increased when it is combined with Diltiazem.Approved
DinutuximabThe risk or severity of adverse effects can be increased when Dinutuximab is combined with Arsenic trioxide.Approved
DiphenhydramineDiphenhydramine may increase the QTc-prolonging activities of Arsenic trioxide.Approved
DipyridamoleThe serum concentration of Arsenic trioxide can be increased when it is combined with Dipyridamole.Approved
DisopyramideDisopyramide may increase the QTc-prolonging activities of Arsenic trioxide.Approved
DocetaxelThe risk or severity of adverse effects can be increased when Docetaxel is combined with Arsenic trioxide.Approved, Investigational
DofetilideDofetilide may increase the QTc-prolonging activities of Arsenic trioxide.Approved
DolasetronDolasetron may increase the QTc-prolonging activities of Arsenic trioxide.Approved
DomperidoneArsenic trioxide may increase the QTc-prolonging activities of Domperidone.Approved, Investigational, Vet Approved
DoxazosinThe serum concentration of Arsenic trioxide can be increased when it is combined with Doxazosin.Approved
DoxepinDoxepin may increase the QTc-prolonging activities of Arsenic trioxide.Approved
DoxorubicinThe serum concentration of Arsenic trioxide can be decreased when it is combined with Doxorubicin.Approved, Investigational
DronabinolThe serum concentration of Arsenic trioxide can be increased when it is combined with Dronabinol.Approved, Illicit
DronedaroneArsenic trioxide may increase the QTc-prolonging activities of Dronedarone.Approved
DroperidolDroperidol may increase the QTc-prolonging activities of Arsenic trioxide.Approved, Vet Approved
DulaglutideThe therapeutic efficacy of Dulaglutide can be decreased when used in combination with Arsenic trioxide.Approved
DuloxetineArsenic trioxide may increase the orthostatic hypotensive activities of Duloxetine.Approved
EfonidipineThe risk or severity of adverse effects can be increased when Arsenic trioxide is combined with Efonidipine.Approved
ElbasvirThe serum concentration of Arsenic trioxide can be increased when it is combined with Elbasvir.Approved
EliglustatArsenic trioxide may increase the QTc-prolonging activities of Eliglustat.Approved
EmpagliflozinThe risk or severity of adverse effects can be increased when Empagliflozin is combined with Arsenic trioxide.Approved
EnalaprilThe serum concentration of Arsenic trioxide can be increased when it is combined with Enalapril.Approved, Vet Approved
EnalaprilatThe risk or severity of adverse effects can be increased when Arsenic trioxide is combined with Enalaprilat.Approved
EnzalutamideThe serum concentration of Arsenic trioxide can be increased when it is combined with Enzalutamide.Approved
EplerenoneThe risk or severity of adverse effects can be increased when Eplerenone is combined with Arsenic trioxide.Approved
EpoprostenolThe risk or severity of adverse effects can be increased when Arsenic trioxide is combined with Epoprostenol.Approved
EprosartanThe risk or severity of adverse effects can be increased when Eprosartan is combined with Arsenic trioxide.Approved
ErgonovineThe serum concentration of Arsenic trioxide can be increased when it is combined with Ergonovine.Approved
ErgotamineThe serum concentration of Arsenic trioxide can be increased when it is combined with Ergotamine.Approved
EribulinEribulin may increase the QTc-prolonging activities of Arsenic trioxide.Approved, Investigational
ErythromycinErythromycin may increase the QTc-prolonging activities of Arsenic trioxide.Approved, Vet Approved
EscitalopramArsenic trioxide may increase the QTc-prolonging activities of Escitalopram.Approved, Investigational
EsmololThe risk or severity of adverse effects can be increased when Esmolol is combined with Arsenic trioxide.Approved
EstramustineThe serum concentration of Arsenic trioxide can be increased when it is combined with Estramustine.Approved
EstriolThe serum concentration of Arsenic trioxide can be decreased when it is combined with Estriol.Approved, Vet Approved
EstroneThe serum concentration of Arsenic trioxide can be decreased when it is combined with Estrone.Approved
Etacrynic acidThe risk or severity of adverse effects can be increased when Etacrynic acid is combined with Arsenic trioxide.Approved
EtoposideThe serum concentration of Arsenic trioxide can be increased when it is combined with Etoposide.Approved
EtravirineThe serum concentration of Arsenic trioxide can be increased when it is combined with Etravirine.Approved
ExenatideThe therapeutic efficacy of Exenatide can be decreased when used in combination with Arsenic trioxide.Approved, Investigational
EzogabineEzogabine may increase the QTc-prolonging activities of Arsenic trioxide.Approved
FamotidineFamotidine may increase the QTc-prolonging activities of Arsenic trioxide.Approved
FelbamateFelbamate may increase the QTc-prolonging activities of Arsenic trioxide.Approved
FelodipineThe serum concentration of Arsenic trioxide can be increased when it is combined with Felodipine.Approved, Investigational
FenoldopamThe risk or severity of adverse effects can be increased when Arsenic trioxide is combined with Fenoldopam.Approved
FentanylThe serum concentration of Arsenic trioxide can be increased when it is combined with Fentanyl.Approved, Illicit, Investigational, Vet Approved
FexofenadineThe serum concentration of Arsenic trioxide can be increased when it is combined with Fexofenadine.Approved
FidaxomicinThe serum concentration of Arsenic trioxide can be increased when it is combined with Fidaxomicin.Approved
FimasartanThe risk or severity of adverse effects can be increased when Arsenic trioxide is combined with Fimasartan.Approved
FingolimodFingolimod may increase the QTc-prolonging activities of Arsenic trioxide.Approved, Investigational
FlecainideFlecainide may increase the QTc-prolonging activities of Arsenic trioxide.Approved, Withdrawn
FluconazoleFluconazole may increase the QTc-prolonging activities of Arsenic trioxide.Approved
FluoxetineFluoxetine may increase the QTc-prolonging activities of Arsenic trioxide.Approved, Vet Approved
FlupentixolFlupentixol may increase the QTc-prolonging activities of Arsenic trioxide.Approved, Withdrawn
FluphenazineThe serum concentration of Arsenic trioxide can be increased when it is combined with Fluphenazine.Approved
FlurazepamThe serum concentration of Arsenic trioxide can be increased when it is combined with Flurazepam.Approved, Illicit
FluvoxamineThe serum concentration of Arsenic trioxide can be increased when it is combined with Fluvoxamine.Approved, Investigational
FormoterolFormoterol may increase the QTc-prolonging activities of Arsenic trioxide.Approved, Investigational
FoscarnetFoscarnet may increase the QTc-prolonging activities of Arsenic trioxide.Approved
FosinoprilThe risk or severity of adverse effects can be increased when Fosinopril is combined with Arsenic trioxide.Approved
FurosemideThe risk or severity of adverse effects can be increased when Furosemide is combined with Arsenic trioxide.Approved, Vet Approved
Gadobenic acidGadobenic acid may increase the QTc-prolonging activities of Arsenic trioxide.Approved
GalantamineGalantamine may increase the QTc-prolonging activities of Arsenic trioxide.Approved
GefitinibThe serum concentration of Arsenic trioxide can be increased when it is combined with Gefitinib.Approved, Investigational
GemifloxacinGemifloxacin may increase the QTc-prolonging activities of Arsenic trioxide.Approved, Investigational
GenisteinThe serum concentration of Arsenic trioxide can be increased when it is combined with Genistein.Investigational
GlibornurideThe therapeutic efficacy of Glibornuride can be decreased when used in combination with Arsenic trioxide.Withdrawn
GliclazideThe therapeutic efficacy of Gliclazide can be decreased when used in combination with Arsenic trioxide.Approved
GlimepirideThe therapeutic efficacy of Glimepiride can be decreased when used in combination with Arsenic trioxide.Approved
GlipizideThe therapeutic efficacy of Glipizide can be decreased when used in combination with Arsenic trioxide.Approved
GliquidoneThe therapeutic efficacy of Gliquidone can be decreased when used in combination with Arsenic trioxide.Approved
GlyburideThe serum concentration of Arsenic trioxide can be increased when it is combined with Glyburide.Approved
GlycerolThe serum concentration of Arsenic trioxide can be increased when it is combined with Glycerol.Experimental
GoserelinGoserelin may increase the QTc-prolonging activities of Arsenic trioxide.Approved
Gramicidin DThe serum concentration of Arsenic trioxide can be increased when it is combined with Gramicidin D.Approved
GranisetronGranisetron may increase the QTc-prolonging activities of Arsenic trioxide.Approved, Investigational
GrepafloxacinThe serum concentration of Arsenic trioxide can be increased when it is combined with Grepafloxacin.Withdrawn
GuanfacineThe risk or severity of adverse effects can be increased when Guanfacine is combined with Arsenic trioxide.Approved, Investigational
GusperimusThe therapeutic efficacy of Gusperimus can be decreased when used in combination with Arsenic trioxide.Investigational
HaloperidolHaloperidol may increase the QTc-prolonging activities of Arsenic trioxide.Approved
HalothaneThe risk or severity of adverse effects can be increased when Arsenic trioxide is combined with Halothane.Approved, Vet Approved
HexobarbitalHexobarbital may increase the hypotensive activities of Arsenic trioxide.Approved
HistrelinHistrelin may increase the QTc-prolonging activities of Arsenic trioxide.Approved
HydralazineThe risk or severity of adverse effects can be increased when Hydralazine is combined with Arsenic trioxide.Approved
HydrochlorothiazideThe risk or severity of adverse effects can be increased when Hydrochlorothiazide is combined with Arsenic trioxide.Approved, Vet Approved
HydrocortisoneThe serum concentration of Arsenic trioxide can be increased when it is combined with Hydrocortisone.Approved, Vet Approved
HydroflumethiazideThe risk or severity of adverse effects can be increased when Arsenic trioxide is combined with Hydroflumethiazide.Approved
HydroxyzineHydroxyzine may increase the QTc-prolonging activities of Arsenic trioxide.Approved
IbandronateIbandronate may increase the QTc-prolonging activities of Arsenic trioxide.Approved, Investigational
IbutilideIbutilide may increase the QTc-prolonging activities of Arsenic trioxide.Approved
IdelalisibThe serum concentration of Arsenic trioxide can be increased when it is combined with Idelalisib.Approved
IloperidoneArsenic trioxide may increase the QTc-prolonging activities of Iloperidone.Approved
IloprostThe risk or severity of adverse effects can be increased when Arsenic trioxide is combined with Iloprost.Approved, Investigational
ImatinibThe serum concentration of Arsenic trioxide can be increased when it is combined with Imatinib.Approved
ImidaprilThe risk or severity of adverse effects can be increased when Arsenic trioxide is combined with Imidapril.Investigational
ImipramineImipramine may increase the QTc-prolonging activities of Arsenic trioxide.Approved
IndacaterolIndacaterol may increase the QTc-prolonging activities of Arsenic trioxide.Approved
IndapamideIndapamide may increase the QTc-prolonging activities of Arsenic trioxide.Approved
IndinavirThe serum concentration of Arsenic trioxide can be decreased when it is combined with Indinavir.Approved
IndomethacinThe serum concentration of Arsenic trioxide can be increased when it is combined with Indomethacin.Approved, Investigational
IndoraminThe risk or severity of adverse effects can be increased when Arsenic trioxide is combined with Indoramin.Withdrawn
Insulin AspartThe therapeutic efficacy of Insulin Aspart can be decreased when used in combination with Arsenic trioxide.Approved
Insulin DetemirThe therapeutic efficacy of Insulin Detemir can be decreased when used in combination with Arsenic trioxide.Approved
Insulin GlargineThe therapeutic efficacy of Insulin Glargine can be decreased when used in combination with Arsenic trioxide.Approved
Insulin GlulisineThe therapeutic efficacy of Insulin Glulisine can be decreased when used in combination with Arsenic trioxide.Approved
Insulin LisproThe therapeutic efficacy of Insulin Lispro can be decreased when used in combination with Arsenic trioxide.Approved
Insulin PorkThe therapeutic efficacy of Insulin Pork can be decreased when used in combination with Arsenic trioxide.Approved
IrbesartanThe risk or severity of adverse effects can be increased when Irbesartan is combined with Arsenic trioxide.Approved, Investigational
IsavuconazoniumThe serum concentration of Arsenic trioxide can be increased when it is combined with Isavuconazonium.Approved, Investigational
IsocarboxazidThe risk or severity of adverse effects can be increased when Arsenic trioxide is combined with Isocarboxazid.Approved
IsofluraneIsoflurane may increase the QTc-prolonging activities of Arsenic trioxide.Approved, Vet Approved
Isosorbide DinitrateThe risk or severity of adverse effects can be increased when Isosorbide Dinitrate is combined with Arsenic trioxide.Approved
Isosorbide MononitrateThe risk or severity of adverse effects can be increased when Isosorbide Mononitrate is combined with Arsenic trioxide.Approved
IsoxsuprineThe risk or severity of adverse effects can be increased when Isoxsuprine is combined with Arsenic trioxide.Approved, Withdrawn
IsradipineIsradipine may increase the QTc-prolonging activities of Arsenic trioxide.Approved
ItraconazoleItraconazole may increase the QTc-prolonging activities of Arsenic trioxide.Approved, Investigational
IvabradineIvabradine may increase the QTc-prolonging activities of Arsenic trioxide.Approved
IvacaftorThe serum concentration of Arsenic trioxide can be increased when it is combined with Ivacaftor.Approved
IvermectinThe serum concentration of Arsenic trioxide can be increased when it is combined with Ivermectin.Approved, Vet Approved
KetamineThe serum concentration of Arsenic trioxide can be increased when it is combined with Ketamine.Approved, Vet Approved
KetoconazoleKetoconazole may increase the QTc-prolonging activities of Arsenic trioxide.Approved, Investigational
LabetalolThe risk or severity of adverse effects can be increased when Labetalol is combined with Arsenic trioxide.Approved
LacidipineThe risk or severity of adverse effects can be increased when Arsenic trioxide is combined with Lacidipine.Approved
LansoprazoleThe serum concentration of Arsenic trioxide can be increased when it is combined with Lansoprazole.Approved, Investigational
LapatinibLapatinib may increase the QTc-prolonging activities of Arsenic trioxide.Approved, Investigational
LenvatinibLenvatinib may increase the QTc-prolonging activities of Arsenic trioxide.Approved
LercanidipineThe risk or severity of adverse effects can be increased when Arsenic trioxide is combined with Lercanidipine.Approved, Investigational
LeuprolideLeuprolide may increase the QTc-prolonging activities of Arsenic trioxide.Approved, Investigational
LevobunololThe risk or severity of adverse effects can be increased when Levobunolol is combined with Arsenic trioxide.Approved
LevobupivacaineThe risk or severity of adverse effects can be increased when Arsenic trioxide is combined with Levobupivacaine.Approved
LevodopaArsenic trioxide may increase the orthostatic hypotensive activities of Levodopa.Approved
LevofloxacinLevofloxacin may increase the QTc-prolonging activities of Arsenic trioxide.Approved, Investigational
LevosimendanThe risk or severity of adverse effects can be increased when Arsenic trioxide is combined with Levosimendan.Approved, Investigational
LevothyroxineThe serum concentration of Arsenic trioxide can be decreased when it is combined with Levothyroxine.Approved
LidocaineThe serum concentration of Arsenic trioxide can be increased when it is combined with Lidocaine.Approved, Vet Approved
LinagliptinThe therapeutic efficacy of Linagliptin can be decreased when used in combination with Arsenic trioxide.Approved
LiothyronineThe serum concentration of Arsenic trioxide can be decreased when it is combined with Liothyronine.Approved, Vet Approved
LiotrixThe serum concentration of Arsenic trioxide can be decreased when it is combined with Liotrix.Approved
LiraglutideThe therapeutic efficacy of Liraglutide can be decreased when used in combination with Arsenic trioxide.Approved
LisinoprilThe serum concentration of Arsenic trioxide can be increased when it is combined with Lisinopril.Approved, Investigational
LithiumLithium may increase the QTc-prolonging activities of Arsenic trioxide.Approved
LofexidineThe risk or severity of adverse effects can be increased when Arsenic trioxide is combined with Lofexidine.Approved, Investigational
LomitapideThe serum concentration of Arsenic trioxide can be increased when it is combined with Lomitapide.Approved
LoperamideThe serum concentration of Arsenic trioxide can be increased when it is combined with Loperamide.Approved
LopinavirArsenic trioxide may increase the QTc-prolonging activities of Lopinavir.Approved
LoratadineThe serum concentration of Arsenic trioxide can be increased when it is combined with Loratadine.Approved
LosartanThe serum concentration of Arsenic trioxide can be increased when it is combined with Losartan.Approved
LovastatinThe serum concentration of Arsenic trioxide can be increased when it is combined with Lovastatin.Approved, Investigational
LumacaftorThe serum concentration of Arsenic trioxide can be decreased when it is combined with Lumacaftor.Approved
LumefantrineArsenic trioxide may increase the QTc-prolonging activities of Lumefantrine.Approved
MannitolThe risk or severity of adverse effects can be increased when Mannitol is combined with Arsenic trioxide.Approved, Investigational
MaprotilineMaprotiline may increase the QTc-prolonging activities of Arsenic trioxide.Approved
MebendazoleThe serum concentration of Arsenic trioxide can be increased when it is combined with Mebendazole.Approved, Vet Approved
MecamylamineThe risk or severity of adverse effects can be increased when Mecamylamine is combined with Arsenic trioxide.Approved
MefloquineMefloquine may increase the QTc-prolonging activities of Arsenic trioxide.Approved
Megestrol acetateThe serum concentration of Arsenic trioxide can be increased when it is combined with Megestrol acetate.Approved, Vet Approved
MeprobamateThe serum concentration of Arsenic trioxide can be increased when it is combined with Meprobamate.Approved, Illicit
MetamizoleThe risk or severity of adverse effects can be increased when Metamizole is combined with Arsenic trioxide.Withdrawn
MetforminThe therapeutic efficacy of Metformin can be decreased when used in combination with Arsenic trioxide.Approved
MethadoneMethadone may increase the QTc-prolonging activities of Arsenic trioxide.Approved
MethazolamideThe risk or severity of adverse effects can be increased when Methazolamide is combined with Arsenic trioxide.Approved
MethohexitalMethohexital may increase the hypotensive activities of Arsenic trioxide.Approved
MethotrimeprazineMethotrimeprazine may increase the QTc-prolonging activities of Arsenic trioxide.Approved
MethyclothiazideThe risk or severity of adverse effects can be increased when Methyclothiazide is combined with Arsenic trioxide.Approved
MethyldopaThe risk or severity of adverse effects can be increased when Methyldopa is combined with Arsenic trioxide.Approved
MethylphenobarbitalMethylphenobarbital may increase the hypotensive activities of Arsenic trioxide.Approved
MetipranololThe risk or severity of adverse effects can be increased when Metipranolol is combined with Arsenic trioxide.Approved
MetoclopramideMetoclopramide may increase the QTc-prolonging activities of Arsenic trioxide.Approved, Investigational
MetolazoneThe risk or severity of adverse effects can be increased when Metolazone is combined with Arsenic trioxide.Approved
MetoprololThe serum concentration of Arsenic trioxide can be increased when it is combined with Metoprolol.Approved, Investigational
MetronidazoleMetronidazole may increase the QTc-prolonging activities of Arsenic trioxide.Approved
MibefradilThe serum concentration of Arsenic trioxide can be increased when it is combined with Mibefradil.Withdrawn
MiconazoleThe serum concentration of Arsenic trioxide can be increased when it is combined with Miconazole.Approved, Investigational, Vet Approved
MidazolamThe serum concentration of Arsenic trioxide can be decreased when it is combined with Midazolam.Approved, Illicit
MifepristoneMifepristone may increase the QTc-prolonging activities of Arsenic trioxide.Approved, Investigational
MiglitolThe therapeutic efficacy of Miglitol can be decreased when used in combination with Arsenic trioxide.Approved
MiglustatThe therapeutic efficacy of Miglustat can be decreased when used in combination with Arsenic trioxide.Approved
MinoxidilThe risk or severity of adverse effects can be increased when Minoxidil is combined with Arsenic trioxide.Approved
MirabegronMirabegron may increase the QTc-prolonging activities of Arsenic trioxide.Approved
MirtazapineMirtazapine may increase the QTc-prolonging activities of Arsenic trioxide.Approved
MitiglinideThe therapeutic efficacy of Mitiglinide can be decreased when used in combination with Arsenic trioxide.Approved, Investigational
MitomycinThe serum concentration of Arsenic trioxide can be increased when it is combined with Mitomycin.Approved
MitoxantroneThe serum concentration of Arsenic trioxide can be decreased when it is combined with Mitoxantrone.Approved, Investigational
MoexiprilMoexipril may increase the QTc-prolonging activities of Arsenic trioxide.Approved
MorphineThe serum concentration of Arsenic trioxide can be increased when it is combined with Morphine.Approved, Investigational
MoxifloxacinMoxifloxacin may increase the QTc-prolonging activities of Arsenic trioxide.Approved, Investigational
MoxonidineThe risk or severity of adverse effects can be increased when Arsenic trioxide is combined with Moxonidine.Approved
NabiloneThe risk or severity of adverse effects can be increased when Arsenic trioxide is combined with Nabilone.Approved, Investigational
NadololThe risk or severity of adverse effects can be increased when Nadolol is combined with Arsenic trioxide.Approved
NaltrexoneThe serum concentration of Arsenic trioxide can be increased when it is combined with Naltrexone.Approved, Investigational, Vet Approved
NaringeninThe serum concentration of Arsenic trioxide can be increased when it is combined with Naringenin.Experimental
NateglinideThe therapeutic efficacy of Nateglinide can be decreased when used in combination with Arsenic trioxide.Approved, Investigational
NebivololThe risk or severity of adverse effects can be increased when Nebivolol is combined with Arsenic trioxide.Approved, Investigational
NefazodoneThe serum concentration of Arsenic trioxide can be decreased when it is combined with Nefazodone.Approved, Withdrawn
NelfinavirNelfinavir may increase the QTc-prolonging activities of Arsenic trioxide.Approved
NeostigmineThe serum concentration of Arsenic trioxide can be increased when it is combined with Neostigmine.Approved, Vet Approved
NesiritideThe risk or severity of adverse effects can be increased when Nesiritide is combined with Arsenic trioxide.Approved, Investigational
NicardipineNicardipine may increase the QTc-prolonging activities of Arsenic trioxide.Approved
NicorandilNicorandil may increase the hypotensive activities of Arsenic trioxide.Approved
NifedipineThe serum concentration of Arsenic trioxide can be decreased when it is combined with Nifedipine.Approved
NilotinibArsenic trioxide may increase the QTc-prolonging activities of Nilotinib.Approved, Investigational
NilvadipineThe risk or severity of adverse effects can be increased when Arsenic trioxide is combined with Nilvadipine.Approved
NimodipineThe risk or severity of adverse effects can be increased when Nimodipine is combined with Arsenic trioxide.Approved
NisoldipineThe serum concentration of Arsenic trioxide can be increased when it is combined with Nisoldipine.Approved
NitrazepamThe serum concentration of Arsenic trioxide can be increased when it is combined with Nitrazepam.Approved
NitrendipineThe serum concentration of Arsenic trioxide can be increased when it is combined with Nitrendipine.Approved
Nitric OxideThe risk or severity of adverse effects can be increased when Arsenic trioxide is combined with Nitric Oxide.Approved
NitroglycerinThe risk or severity of adverse effects can be increased when Nitroglycerin is combined with Arsenic trioxide.Approved, Investigational
NitroprussideThe risk or severity of adverse effects can be increased when Nitroprusside is combined with Arsenic trioxide.Approved
NorethisteroneThe serum concentration of Arsenic trioxide can be decreased when it is combined with Norethisterone.Approved
NorfloxacinNorfloxacin may increase the QTc-prolonging activities of Arsenic trioxide.Approved
NortriptylineNortriptyline may increase the QTc-prolonging activities of Arsenic trioxide.Approved
ObinutuzumabThe risk or severity of adverse effects can be increased when Arsenic trioxide is combined with Obinutuzumab.Approved
OctreotideOctreotide may increase the QTc-prolonging activities of Arsenic trioxide.Approved, Investigational
OfloxacinOfloxacin may increase the QTc-prolonging activities of Arsenic trioxide.Approved
OlanzapineOlanzapine may increase the QTc-prolonging activities of Arsenic trioxide.Approved, Investigational
OlmesartanThe risk or severity of adverse effects can be increased when Olmesartan is combined with Arsenic trioxide.Approved, Investigational
OlodaterolOlodaterol may increase the QTc-prolonging activities of Arsenic trioxide.Approved
OmeprazoleThe serum concentration of Arsenic trioxide can be increased when it is combined with Omeprazole.Approved, Investigational, Vet Approved
OndansetronOndansetron may increase the QTc-prolonging activities of Arsenic trioxide.Approved
OuabainOuabain may decrease the cardiotoxic activities of Arsenic trioxide.Approved
OxprenololThe risk or severity of adverse effects can be increased when Arsenic trioxide is combined with Oxprenolol.Approved
OxytocinOxytocin may increase the QTc-prolonging activities of Arsenic trioxide.Approved, Vet Approved
P-NitrophenolThe serum concentration of Arsenic trioxide can be increased when it is combined with P-Nitrophenol.Experimental
PaclitaxelThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Arsenic trioxide.Approved, Vet Approved
PaliperidoneArsenic trioxide may increase the QTc-prolonging activities of Paliperidone.Approved
Palmitic AcidThe serum concentration of Arsenic trioxide can be increased when it is combined with Palmitic Acid.Experimental
PanobinostatPanobinostat may increase the QTc-prolonging activities of Arsenic trioxide.Approved, Investigational
PantoprazoleThe serum concentration of Arsenic trioxide can be increased when it is combined with Pantoprazole.Approved
PapaverineThe risk or severity of adverse effects can be increased when Papaverine is combined with Arsenic trioxide.Approved
ParoxetineParoxetine may increase the QTc-prolonging activities of Arsenic trioxide.Approved, Investigational
PasireotidePasireotide may increase the QTc-prolonging activities of Arsenic trioxide.Approved
PazopanibPazopanib may increase the QTc-prolonging activities of Arsenic trioxide.Approved
PenbutololThe risk or severity of adverse effects can be increased when Penbutolol is combined with Arsenic trioxide.Approved, Investigational
PentamidinePentamidine may increase the QTc-prolonging activities of Arsenic trioxide.Approved
PentobarbitalPentobarbital may increase the hypotensive activities of Arsenic trioxide.Approved, Vet Approved
PerflutrenPerflutren may increase the QTc-prolonging activities of Arsenic trioxide.Approved
PerindoprilThe serum concentration of Arsenic trioxide can be increased when it is combined with Perindopril.Approved
PhenelzineThe risk or severity of adverse effects can be increased when Arsenic trioxide is combined with Phenelzine.Approved
PhenforminThe therapeutic efficacy of Phenformin can be decreased when used in combination with Arsenic trioxide.Approved, Withdrawn
PhenobarbitalThe serum concentration of Arsenic trioxide can be decreased when it is combined with Phenobarbital.Approved
PhenoxybenzamineThe risk or severity of adverse effects can be increased when Arsenic trioxide is combined with Phenoxybenzamine.Approved
PhentolamineThe risk or severity of adverse effects can be increased when Arsenic trioxide is combined with Phentolamine.Approved
PimozidePimozide may increase the QTc-prolonging activities of Arsenic trioxide.Approved
PindololThe risk or severity of adverse effects can be increased when Pindolol is combined with Arsenic trioxide.Approved
PioglitazoneThe therapeutic efficacy of Pioglitazone can be decreased when used in combination with Arsenic trioxide.Approved, Investigational
PipamperoneThe risk or severity of adverse effects can be increased when Arsenic trioxide is combined with Pipamperone.Approved
Platelet Activating FactorThe serum concentration of Arsenic trioxide can be decreased when it is combined with Platelet Activating Factor.Experimental
PonatinibThe serum concentration of Arsenic trioxide can be increased when it is combined with Ponatinib.Approved
PosaconazolePosaconazole may increase the QTc-prolonging activities of Arsenic trioxide.Approved, Investigational, Vet Approved
PramipexoleThe risk or severity of adverse effects can be increased when Arsenic trioxide is combined with Pramipexole.Approved, Investigational
PramlintideThe therapeutic efficacy of Pramlintide can be decreased when used in combination with Arsenic trioxide.Approved, Investigational
PravastatinThe serum concentration of Arsenic trioxide can be increased when it is combined with Pravastatin.Approved
PrazosinThe serum concentration of Arsenic trioxide can be increased when it is combined with Prazosin.Approved
PrednisoneThe serum concentration of Arsenic trioxide can be increased when it is combined with Prednisone.Approved, Vet Approved
PrimaquinePrimaquine may increase the QTc-prolonging activities of Arsenic trioxide.Approved
PrimidonePrimidone may increase the hypotensive activities of Arsenic trioxide.Approved, Vet Approved
ProbenecidThe serum concentration of Arsenic trioxide can be increased when it is combined with Probenecid.Approved
ProcainamideProcainamide may increase the QTc-prolonging activities of Arsenic trioxide.Approved
ProgesteroneThe serum concentration of Arsenic trioxide can be decreased when it is combined with Progesterone.Approved, Vet Approved
PromazinePromazine may increase the QTc-prolonging activities of Arsenic trioxide.Approved, Vet Approved
PromethazinePromethazine may increase the QTc-prolonging activities of Arsenic trioxide.Approved
PropafenonePropafenone may increase the QTc-prolonging activities of Arsenic trioxide.Approved
PropofolPropofol may increase the QTc-prolonging activities of Arsenic trioxide.Approved, Investigational, Vet Approved
PropranololThe serum concentration of Arsenic trioxide can be increased when it is combined with Propranolol.Approved, Investigational
ProtriptylineProtriptyline may increase the QTc-prolonging activities of Arsenic trioxide.Approved
QuercetinThe serum concentration of Arsenic trioxide can be increased when it is combined with Quercetin.Experimental
QuetiapineArsenic trioxide may increase the QTc-prolonging activities of Quetiapine.Approved
QuinacrineThe serum concentration of Arsenic trioxide can be increased when it is combined with Quinacrine.Approved
QuinaprilThe risk or severity of adverse effects can be increased when Quinapril is combined with Arsenic trioxide.Approved, Investigational
QuinidineQuinidine may increase the QTc-prolonging activities of Arsenic trioxide.Approved
QuinineQuinine may increase the QTc-prolonging activities of Arsenic trioxide.Approved
RamiprilThe risk or severity of adverse effects can be increased when Ramipril is combined with Arsenic trioxide.Approved
RanitidineThe serum concentration of Arsenic trioxide can be increased when it is combined with Ranitidine.Approved
RanolazineThe serum concentration of Arsenic trioxide can be increased when it is combined with Ranolazine.Approved, Investigational
RasagilineThe risk or severity of adverse effects can be increased when Arsenic trioxide is combined with Rasagiline.Approved
ReboxetineThe serum concentration of Arsenic trioxide can be increased when it is combined with Reboxetine.Approved, Investigational
RegorafenibThe serum concentration of Arsenic trioxide can be increased when it is combined with Regorafenib.Approved
RemifentanilThe risk or severity of adverse effects can be increased when Arsenic trioxide is combined with Remifentanil.Approved
RepaglinideThe therapeutic efficacy of Repaglinide can be decreased when used in combination with Arsenic trioxide.Approved, Investigational
ReserpineThe serum concentration of Arsenic trioxide can be decreased when it is combined with Reserpine.Approved
RifampicinThe serum concentration of Arsenic trioxide can be decreased when it is combined with Rifampicin.Approved
RilpivirineRilpivirine may increase the QTc-prolonging activities of Arsenic trioxide.Approved
RiociguatThe risk or severity of adverse effects can be increased when Riociguat is combined with Arsenic trioxide.Approved
RisperidoneArsenic trioxide may increase the hypotensive activities of Risperidone.Approved, Investigational
RitonavirRitonavir may increase the QTc-prolonging activities of Arsenic trioxide.Approved, Investigational
RolapitantThe serum concentration of Arsenic trioxide can be increased when it is combined with Rolapitant.Approved
RopiniroleThe risk or severity of adverse effects can be increased when Arsenic trioxide is combined with Ropinirole.Approved, Investigational
RopivacaineThe risk or severity of adverse effects can be increased when Arsenic trioxide is combined with Ropivacaine.Approved
RosiglitazoneThe therapeutic efficacy of Rosiglitazone can be decreased when used in combination with Arsenic trioxide.Approved, Investigational
RotigotineThe risk or severity of adverse effects can be increased when Arsenic trioxide is combined with Rotigotine.Approved
SacubitrilThe risk or severity of adverse effects can be increased when Arsenic trioxide is combined with Sacubitril.Approved
SalbutamolSalbutamol may increase the QTc-prolonging activities of Arsenic trioxide.Approved, Vet Approved
SalmeterolSalmeterol may increase the QTc-prolonging activities of Arsenic trioxide.Approved
SaquinavirSaquinavir may increase the QTc-prolonging activities of Arsenic trioxide.Approved, Investigational
SaxagliptinThe therapeutic efficacy of Saxagliptin can be decreased when used in combination with Arsenic trioxide.Approved
ScopolamineThe serum concentration of Arsenic trioxide can be increased when it is combined with Scopolamine.Approved
SecobarbitalSecobarbital may increase the hypotensive activities of Arsenic trioxide.Approved, Vet Approved
SelegilineThe serum concentration of Arsenic trioxide can be increased when it is combined with Selegiline.Approved, Investigational, Vet Approved
SertralineSertraline may increase the QTc-prolonging activities of Arsenic trioxide.Approved
SevofluraneSevoflurane may increase the QTc-prolonging activities of Arsenic trioxide.Approved, Vet Approved
SimeprevirThe serum concentration of Arsenic trioxide can be increased when it is combined with Simeprevir.Approved
SimvastatinThe serum concentration of Arsenic trioxide can be increased when it is combined with Simvastatin.Approved
SirolimusThe serum concentration of Arsenic trioxide can be decreased when it is combined with Sirolimus.Approved, Investigational
SitagliptinThe therapeutic efficacy of Sitagliptin can be decreased when used in combination with Arsenic trioxide.Approved, Investigational
Sodium NitriteThe risk or severity of adverse effects can be increased when Arsenic trioxide is combined with Sodium Nitrite.Approved
SolifenacinSolifenacin may increase the QTc-prolonging activities of Arsenic trioxide.Approved
SorafenibSorafenib may increase the QTc-prolonging activities of Arsenic trioxide.Approved, Investigational
SotalolSotalol may increase the QTc-prolonging activities of Arsenic trioxide.Approved
SpironolactoneThe serum concentration of Arsenic trioxide can be increased when it is combined with Spironolactone.Approved
St. John's WortThe serum concentration of Arsenic trioxide can be decreased when it is combined with St. John's Wort.Nutraceutical
StaurosporineThe serum concentration of Arsenic trioxide can be increased when it is combined with Staurosporine.Experimental
StreptokinaseThe risk or severity of adverse effects can be increased when Arsenic trioxide is combined with Streptokinase.Approved
StreptozocinThe serum concentration of Arsenic trioxide can be decreased when it is combined with Streptozocin.Approved
SufentanilThe risk or severity of adverse effects can be increased when Arsenic trioxide is combined with Sufentanil.Approved, Investigational
SulfamethoxazoleSulfamethoxazole may increase the QTc-prolonging activities of Arsenic trioxide.Approved
SulfinpyrazoneThe serum concentration of Arsenic trioxide can be increased when it is combined with Sulfinpyrazone.Approved
SulfisoxazoleSulfisoxazole may increase the QTc-prolonging activities of Arsenic trioxide.Approved, Vet Approved
SulodexideThe therapeutic efficacy of Sulodexide can be decreased when used in combination with Arsenic trioxide.Approved, Investigational
SumatriptanThe serum concentration of Arsenic trioxide can be increased when it is combined with Sumatriptan.Approved, Investigational
SunitinibSunitinib may increase the QTc-prolonging activities of Arsenic trioxide.Approved, Investigational
TacrineThe serum concentration of Arsenic trioxide can be increased when it is combined with Tacrine.Withdrawn
TacrolimusThe serum concentration of Arsenic trioxide can be decreased when it is combined with Tacrolimus.Approved, Investigational
TamoxifenTamoxifen may increase the QTc-prolonging activities of Arsenic trioxide.Approved
TamsulosinThe risk or severity of adverse effects can be increased when Arsenic trioxide is combined with Tamsulosin.Approved, Investigational
Taurocholic AcidThe serum concentration of Arsenic trioxide can be increased when it is combined with Taurocholic Acid.Experimental
TelavancinTelavancin may increase the QTc-prolonging activities of Arsenic trioxide.Approved
TelithromycinTelithromycin may increase the QTc-prolonging activities of Arsenic trioxide.Approved
TelmisartanThe serum concentration of Arsenic trioxide can be increased when it is combined with Telmisartan.Approved, Investigational
TemsirolimusThe serum concentration of Arsenic trioxide can be increased when it is combined with Temsirolimus.Approved
TerazosinThe serum concentration of Arsenic trioxide can be increased when it is combined with Terazosin.Approved
TerbutalineTerbutaline may increase the QTc-prolonging activities of Arsenic trioxide.Approved
TerfenadineThe serum concentration of Arsenic trioxide can be increased when it is combined with Terfenadine.Withdrawn
TesmilifeneThe serum concentration of Arsenic trioxide can be decreased when it is combined with Tesmilifene.Investigational
TestosteroneThe serum concentration of Arsenic trioxide can be increased when it is combined with Testosterone.Approved, Investigational
TetrabenazineArsenic trioxide may increase the QTc-prolonging activities of Tetrabenazine.Approved
ThalidomideThe risk or severity of adverse effects can be increased when Arsenic trioxide is combined with Thalidomide.Approved, Investigational, Withdrawn
ThiamylalThiamylal may increase the hypotensive activities of Arsenic trioxide.Approved, Vet Approved
ThiazolidinedioneThe therapeutic efficacy of Thiazolidinedione can be decreased when used in combination with Arsenic trioxide.Investigational
ThiopentalThiopental may increase the hypotensive activities of Arsenic trioxide.Approved, Vet Approved
ThioridazineThioridazine may increase the QTc-prolonging activities of Arsenic trioxide.Approved
ThiothixeneThiothixene may increase the QTc-prolonging activities of Arsenic trioxide.Approved
TicagrelorThe serum concentration of Arsenic trioxide can be increased when it is combined with Ticagrelor.Approved
TimololThe risk or severity of adverse effects can be increased when Timolol is combined with Arsenic trioxide.Approved
TizanidineTizanidine may increase the QTc-prolonging activities of Arsenic trioxide.Approved
TolazamideThe therapeutic efficacy of Tolazamide can be decreased when used in combination with Arsenic trioxide.Approved
TolazolineThe risk or severity of adverse effects can be increased when Arsenic trioxide is combined with Tolazoline.Approved, Vet Approved
TolbutamideThe therapeutic efficacy of Tolbutamide can be decreased when used in combination with Arsenic trioxide.Approved
TolcaponeThe risk or severity of adverse effects can be increased when Arsenic trioxide is combined with Tolcapone.Approved, Withdrawn
TolterodineTolterodine may increase the QTc-prolonging activities of Arsenic trioxide.Approved, Investigational
TolvaptanThe serum concentration of Arsenic trioxide can be increased when it is combined with Tolvaptan.Approved
TorasemideThe risk or severity of adverse effects can be increased when Torasemide is combined with Arsenic trioxide.Approved
ToremifeneToremifene may increase the QTc-prolonging activities of Arsenic trioxide.Approved, Investigational
TrandolaprilThe risk or severity of adverse effects can be increased when Trandolapril is combined with Arsenic trioxide.Approved
TranylcypromineThe risk or severity of adverse effects can be increased when Arsenic trioxide is combined with Tranylcypromine.Approved
TrastuzumabTrastuzumab may increase the cardiotoxic activities of Arsenic trioxide.Approved, Investigational
TrazodoneTrazodone may increase the QTc-prolonging activities of Arsenic trioxide.Approved, Investigational
TreprostinilTreprostinil may increase the QTc-prolonging activities of Arsenic trioxide.Approved, Investigational
TretinoinThe risk or severity of adverse effects can be increased when Arsenic trioxide is combined with Tretinoin.Approved, Investigational, Nutraceutical
TriamtereneThe risk or severity of adverse effects can be increased when Triamterene is combined with Arsenic trioxide.Approved
TrifluoperazineThe serum concentration of Arsenic trioxide can be increased when it is combined with Trifluoperazine.Approved
TriflupromazineThe serum concentration of Arsenic trioxide can be increased when it is combined with Triflupromazine.Approved, Vet Approved
TrimethoprimTrimethoprim may increase the QTc-prolonging activities of Arsenic trioxide.Approved, Vet Approved
TrimipramineTrimipramine may increase the QTc-prolonging activities of Arsenic trioxide.Approved
TriptorelinTriptorelin may increase the QTc-prolonging activities of Arsenic trioxide.Approved, Vet Approved
TroglitazoneThe therapeutic efficacy of Troglitazone can be decreased when used in combination with Arsenic trioxide.Withdrawn
TroleandomycinThe serum concentration of Arsenic trioxide can be increased when it is combined with Troleandomycin.Approved
ValsartanThe risk or severity of adverse effects can be increased when Valsartan is combined with Arsenic trioxide.Approved, Investigational
VandetanibArsenic trioxide may increase the QTc-prolonging activities of Vandetanib.Approved
VardenafilVardenafil may increase the QTc-prolonging activities of Arsenic trioxide.Approved
VemurafenibArsenic trioxide may increase the QTc-prolonging activities of Vemurafenib.Approved
VenlafaxineVenlafaxine may increase the QTc-prolonging activities of Arsenic trioxide.Approved
VerapamilThe serum concentration of Arsenic trioxide can be decreased when it is combined with Verapamil.Approved
VilanterolVilanterol may increase the QTc-prolonging activities of Arsenic trioxide.Approved
VildagliptinThe therapeutic efficacy of Vildagliptin can be decreased when used in combination with Arsenic trioxide.Approved, Investigational
VinblastineThe serum concentration of Arsenic trioxide can be decreased when it is combined with Vinblastine.Approved
VincristineThe serum concentration of Arsenic trioxide can be decreased when it is combined with Vincristine.Approved, Investigational
VinorelbineThe serum concentration of Arsenic trioxide can be increased when it is combined with Vinorelbine.Approved, Investigational
VogliboseThe therapeutic efficacy of Voglibose can be decreased when used in combination with Arsenic trioxide.Approved, Investigational
VoriconazoleVoriconazole may increase the QTc-prolonging activities of Arsenic trioxide.Approved, Investigational
VorinostatVorinostat may increase the QTc-prolonging activities of Arsenic trioxide.Approved, Investigational
ZimelidineThe serum concentration of Arsenic trioxide can be increased when it is combined with Zimelidine.Withdrawn
ZiprasidoneZiprasidone may increase the QTc-prolonging activities of Arsenic trioxide.Approved
ZuclopenthixolArsenic trioxide may increase the QTc-prolonging activities of Zuclopenthixol.Approved, Investigational
Food InteractionsNot Available
References
Synthesis ReferenceNot Available
General References
  1. Lu J, Chew EH, Holmgren A: Targeting thioredoxin reductase is a basis for cancer therapy by arsenic trioxide. Proc Natl Acad Sci U S A. 2007 Jul 24;104(30):12288-93. Epub 2007 Jul 18. [PubMed:17640917 ]
External Links
ATC CodesL01XX27
AHFS Codes
  • 92:02.00*
PDB EntriesNot Available
FDA labelDownload (46.3 KB)
MSDSDownload (78.3 KB)
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9839
Blood Brain Barrier+0.9549
Caco-2 permeable-0.526
P-glycoprotein substrateNon-substrate0.8227
P-glycoprotein inhibitor INon-inhibitor0.9138
P-glycoprotein inhibitor IINon-inhibitor0.9925
Renal organic cation transporterNon-inhibitor0.9297
CYP450 2C9 substrateNon-substrate0.9036
CYP450 2D6 substrateNon-substrate0.829
CYP450 3A4 substrateNon-substrate0.7462
CYP450 1A2 substrateNon-inhibitor0.7393
CYP450 2C9 inhibitorNon-inhibitor0.8625
CYP450 2D6 inhibitorNon-inhibitor0.9133
CYP450 2C19 inhibitorNon-inhibitor0.7968
CYP450 3A4 inhibitorNon-inhibitor0.9567
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.9743
Ames testNon AMES toxic0.5978
CarcinogenicityNon-carcinogens0.5984
BiodegradationReady biodegradable0.8156
Rat acute toxicity2.5942 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.8253
hERG inhibition (predictor II)Non-inhibitor0.9812
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
ManufacturersNot Available
Packagers
Dosage forms
FormRouteStrength
Injection, solutionIntravenous1 mg/mL
SolutionIntravenous1 mg
Prices
Unit descriptionCostUnit
Trisenox 10 mg/10 ml ampule43.58USD ml
Arsenic trioxide powder2.59USD g
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
US6723351 No1998-11-102018-11-10Us
US6855339 No1998-11-102018-11-10Us
US6861076 No1998-11-102018-11-10Us
US6884439 No1998-11-102018-11-10Us
US6982096 No1998-11-102018-11-10Us
US8273379 No1998-11-102018-11-10Us
Properties
StateSolid
Experimental Properties
PropertyValueSource
water solubility1.7E+004 mg/L (at 16 °C)SHIU,WY ET AL. (1990)
Predicted Properties
PropertyValueSource
logP0.45ChemAxon
pKa (Strongest Basic)-4.8ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count3ChemAxon
Hydrogen Donor Count0ChemAxon
Polar Surface Area51.21 Å2ChemAxon
Rotatable Bond Count1ChemAxon
Refractivity4.33 m3·mol-1ChemAxon
Polarizability6.81 Å3ChemAxon
Number of Rings0ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
SpectraNot Available
Taxonomy
DescriptionThis compound belongs to the class of inorganic compounds known as metalloid oxides. These are inorganic compounds containing an oxygen atom of an oxidation state of -2, in which the heaviest atom bonded to the oxygen is a metalloid.
KingdomInorganic compounds
Super ClassMixed metal/non-metal compounds
ClassMetalloid organides
Sub ClassMetalloid oxides
Direct ParentMetalloid oxides
Alternative Parents
Substituents
  • Metalloid oxide
  • Inorganic oxide
  • Inorganic metalloid salt
  • Inorganic arsenic compound
Molecular FrameworkNot Available
External DescriptorsNot Available

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inducer
General Function:
Scaffold protein binding
Specific Function:
Serine kinase that plays an essential role in the NF-kappa-B signaling pathway which is activated by multiple stimuli such as inflammatory cytokines, bacterial or viral products, DNA damages or other cellular stresses. Acts as part of the canonical IKK complex in the conventional pathway of NF-kappa-B activation and phosphorylates inhibitors of NF-kappa-B on 2 critical serine residues. These mo...
Gene Name:
IKBKB
Uniprot ID:
O14920
Molecular Weight:
86563.245 Da
References
  1. Ouyang W, Ma Q, Li J, Zhang D, Liu ZG, Rustgi AK, Huang C: Cyclin D1 induction through IkappaB kinase beta/nuclear factor-kappaB pathway is responsible for arsenite-induced increased cell cycle G1-S phase transition in human keratinocytes. Cancer Res. 2005 Oct 15;65(20):9287-93. [PubMed:16230390 ]
  2. Ouyang W, Li J, Ma Q, Huang C: Essential roles of PI-3K/Akt/IKKbeta/NFkappaB pathway in cyclin D1 induction by arsenite in JB6 Cl41 cells. Carcinogenesis. 2006 Apr;27(4):864-73. Epub 2005 Dec 29. [PubMed:16387740 ]
  3. Ouyang W, Zhang D, Ma Q, Li J, Huang C: Cyclooxygenase-2 induction by arsenite through the IKKbeta/NFkappaB pathway exerts an antiapoptotic effect in mouse epidermal Cl41 cells. Environ Health Perspect. 2007 Apr;115(4):513-8. Epub 2006 Dec 14. [PubMed:17450217 ]
  4. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inhibitor
General Function:
Thioredoxin-disulfide reductase activity
Specific Function:
Isoform 1 may possess glutaredoxin activity as well as thioredoxin reductase activity and induces actin and tubulin polymerization, leading to formation of cell membrane protrusions. Isoform 4 enhances the transcriptional activity of estrogen receptors alpha and beta while isoform 5 enhances the transcriptional activity of the beta receptor only. Isoform 5 also mediates cell death induced by a ...
Gene Name:
TXNRD1
Uniprot ID:
Q16881
Molecular Weight:
70905.58 Da
References
  1. Lu J, Chew EH, Holmgren A: Targeting thioredoxin reductase is a basis for cancer therapy by arsenic trioxide. Proc Natl Acad Sci U S A. 2007 Jul 24;104(30):12288-93. Epub 2007 Jul 18. [PubMed:17640917 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inducer
General Function:
Transcriptional activator activity, rna polymerase ii transcription factor binding
Specific Function:
Transcription factor that recognizes and binds to the enhancer heptamer motif 5'-TGA[CG]TCA-3'. Promotes activity of NR5A1 when phosphorylated by HIPK3 leading to increased steroidogenic gene expression upon cAMP signaling pathway stimulation.
Gene Name:
JUN
Uniprot ID:
P05412
Molecular Weight:
35675.32 Da
References
  1. Muscarella DE, Bloom SE: Differential activation of the c-Jun N-terminal kinase pathway in arsenite-induced apoptosis and sensitization of chemically resistant compared to susceptible B-lymphoma cell lines. Toxicol Sci. 2002 Jul;68(1):82-92. [PubMed:12075113 ]
  2. Dong Z: The molecular mechanisms of arsenic-induced cell transformation and apoptosis. Environ Health Perspect. 2002 Oct;110 Suppl 5:757-9. [PubMed:12426127 ]
  3. Drobna Z, Jaspers I, Thomas DJ, Styblo M: Differential activation of AP-1 in human bladder epithelial cells by inorganic and methylated arsenicals. FASEB J. 2003 Jan;17(1):67-9. Epub 2002 Nov 15. [PubMed:12475910 ]
  4. Li J, Gorospe M, Barnes J, Liu Y: Tumor promoter arsenite stimulates histone H3 phosphoacetylation of proto-oncogenes c-fos and c-jun chromatin in human diploid fibroblasts. J Biol Chem. 2003 Apr 11;278(15):13183-91. Epub 2003 Jan 23. [PubMed:12547826 ]
  5. Kietzmann T, Samoylenko A, Immenschuh S: Transcriptional regulation of heme oxygenase-1 gene expression by MAP kinases of the JNK and p38 pathways in primary cultures of rat hepatocytes. J Biol Chem. 2003 May 16;278(20):17927-36. Epub 2003 Mar 11. [PubMed:12637567 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
antagonist
General Function:
Transcription factor binding
Specific Function:
Regulatory component of the cyclin D1-CDK4 (DC) complex that phosphorylates and inhibits members of the retinoblastoma (RB) protein family including RB1 and regulates the cell-cycle during G(1)/S transition. Phosphorylation of RB1 allows dissociation of the transcription factor E2F from the RB/E2F complex and the subsequent transcription of E2F target genes which are responsible for the progres...
Gene Name:
CCND1
Uniprot ID:
P24385
Molecular Weight:
33728.74 Da
References
  1. Hyun Park W, Hee Cho Y, Won Jung C, Oh Park J, Kim K, Hyuck Im Y, Lee MH, Ki Kang W, Park K: Arsenic trioxide inhibits the growth of A498 renal cell carcinoma cells via cell cycle arrest or apoptosis. Biochem Biophys Res Commun. 2003 Jan 3;300(1):230-5. [PubMed:12480548 ]
  2. Ouyang W, Ma Q, Li J, Zhang D, Liu ZG, Rustgi AK, Huang C: Cyclin D1 induction through IkappaB kinase beta/nuclear factor-kappaB pathway is responsible for arsenite-induced increased cell cycle G1-S phase transition in human keratinocytes. Cancer Res. 2005 Oct 15;65(20):9287-93. [PubMed:16230390 ]
  3. Ouyang W, Li J, Ma Q, Huang C: Essential roles of PI-3K/Akt/IKKbeta/NFkappaB pathway in cyclin D1 induction by arsenite in JB6 Cl41 cells. Carcinogenesis. 2006 Apr;27(4):864-73. Epub 2005 Dec 29. [PubMed:16387740 ]
  4. Hwang BJ, Utti C, Steinberg M: Induction of cyclin D1 by submicromolar concentrations of arsenite in human epidermal keratinocytes. Toxicol Appl Pharmacol. 2006 Dec 1;217(2):161-7. Epub 2006 Aug 11. [PubMed:17005224 ]
  5. Ouyang W, Li J, Zhang D, Jiang BH, Huang DC: PI-3K/Akt signal pathway plays a crucial role in arsenite-induced cell proliferation of human keratinocytes through induction of cyclin D1. J Cell Biochem. 2007 Jul 1;101(4):969-78. [PubMed:17370311 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inducer
General Function:
Phosphatase binding
Specific Function:
Serine/threonine kinase which acts as an essential component of the MAP kinase signal transduction pathway. MAPK1/ERK2 and MAPK3/ERK1 are the 2 MAPKs which play an important role in the MAPK/ERK cascade. They participate also in a signaling cascade initiated by activated KIT and KITLG/SCF. Depending on the cellular context, the MAPK/ERK cascade mediates diverse biological functions such as cell...
Gene Name:
MAPK3
Uniprot ID:
P27361
Molecular Weight:
43135.16 Da
References
  1. Fauconneau B, Petegnief V, Sanfeliu C, Piriou A, Planas AM: Induction of heat shock proteins (HSPs) by sodium arsenite in cultured astrocytes and reduction of hydrogen peroxide-induced cell death. J Neurochem. 2002 Dec;83(6):1338-48. [PubMed:12472888 ]
  2. Jung DK, Bae GU, Kim YK, Han SH, Choi WS, Kang H, Seo DW, Lee HY, Cho EJ, Lee HW, Han JW: Hydrogen peroxide mediates arsenite activation of p70(s6k) and extracellular signal-regulated kinase. Exp Cell Res. 2003 Oct 15;290(1):144-54. [PubMed:14516795 ]
  3. Tanaka-Kagawa T, Hanioka N, Yoshida H, Jinno H, Ando M: Arsenite and arsenate activate extracellular signal-regulated kinases 1/2 by an epidermal growth factor receptor-mediated pathway in normal human keratinocytes. Br J Dermatol. 2003 Dec;149(6):1116-27. [PubMed:14674888 ]
  4. Felix K, Manna SK, Wise K, Barr J, Ramesh GT: Low levels of arsenite activates nuclear factor-kappaB and activator protein-1 in immortalized mesencephalic cells. J Biochem Mol Toxicol. 2005;19(2):67-77. [PubMed:15849723 ]
  5. Mousa SA, O'Connor L, Rossman TG, Block E: Pro-angiogenesis action of arsenic and its reversal by selenium-derived compounds. Carcinogenesis. 2007 May;28(5):962-7. Epub 2006 Dec 8. [PubMed:17158527 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inducer
General Function:
Rna polymerase ii carboxy-terminal domain kinase activity
Specific Function:
Serine/threonine kinase which acts as an essential component of the MAP kinase signal transduction pathway. MAPK1/ERK2 and MAPK3/ERK1 are the 2 MAPKs which play an important role in the MAPK/ERK cascade. They participate also in a signaling cascade initiated by activated KIT and KITLG/SCF. Depending on the cellular context, the MAPK/ERK cascade mediates diverse biological functions such as cell...
Gene Name:
MAPK1
Uniprot ID:
P28482
Molecular Weight:
41389.265 Da
References
  1. Dong Z: The molecular mechanisms of arsenic-induced cell transformation and apoptosis. Environ Health Perspect. 2002 Oct;110 Suppl 5:757-9. [PubMed:12426127 ]
  2. He Z, Ma WY, Liu G, Zhang Y, Bode AM, Dong Z: Arsenite-induced phosphorylation of histone H3 at serine 10 is mediated by Akt1, extracellular signal-regulated kinase 2, and p90 ribosomal S6 kinase 2 but not mitogen- and stress-activated protein kinase 1. J Biol Chem. 2003 Mar 21;278(12):10588-93. Epub 2003 Jan 14. [PubMed:12529330 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inducer
General Function:
Protein serine/threonine/tyrosine kinase activity
Specific Function:
AKT1 is one of 3 closely related serine/threonine-protein kinases (AKT1, AKT2 and AKT3) called the AKT kinase, and which regulate many processes including metabolism, proliferation, cell survival, growth and angiogenesis. This is mediated through serine and/or threonine phosphorylation of a range of downstream substrates. Over 100 substrate candidates have been reported so far, but for most of ...
Gene Name:
AKT1
Uniprot ID:
P31749
Molecular Weight:
55686.035 Da
References
  1. Fauconneau B, Petegnief V, Sanfeliu C, Piriou A, Planas AM: Induction of heat shock proteins (HSPs) by sodium arsenite in cultured astrocytes and reduction of hydrogen peroxide-induced cell death. J Neurochem. 2002 Dec;83(6):1338-48. [PubMed:12472888 ]
  2. He Z, Ma WY, Liu G, Zhang Y, Bode AM, Dong Z: Arsenite-induced phosphorylation of histone H3 at serine 10 is mediated by Akt1, extracellular signal-regulated kinase 2, and p90 ribosomal S6 kinase 2 but not mitogen- and stress-activated protein kinase 1. J Biol Chem. 2003 Mar 21;278(12):10588-93. Epub 2003 Jan 14. [PubMed:12529330 ]
  3. Ivanov VN, Hei TK: Combined treatment with EGFR inhibitors and arsenite upregulated apoptosis in human EGFR-positive melanomas: a role of suppression of the PI3K-AKT pathway. Oncogene. 2005 Jan 20;24(4):616-26. [PubMed:15580309 ]
  4. Wang ZX, Jiang CS, Liu L, Wang XH, Jin HJ, Wu Q, Chen Q: The role of Akt on arsenic trioxide suppression of 3T3-L1 preadipocyte differentiation. Cell Res. 2005 May;15(5):379-86. [PubMed:15916724 ]
  5. Tsou TC, Tsai FY, Hsieh YW, Li LA, Yeh SC, Chang LW: Arsenite induces endothelial cytotoxicity by down-regulation of vascular endothelial nitric oxide synthase. Toxicol Appl Pharmacol. 2005 Nov 1;208(3):277-84. [PubMed:16239170 ]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Vitamin d 24-hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics.
Gene Name:
CYP1A1
Uniprot ID:
P04798
Molecular Weight:
58164.815 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Oxygen binding
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, retinoid and xenobiotics. Preferentially oxidizes 17beta-estradiol to the carcinogenic 4-hydroxy derivative, and a variety of procarcinogenic compou...
Gene Name:
CYP1B1
Uniprot ID:
Q16678
Molecular Weight:
60845.33 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Vitamin d3 25-hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation reactions (e.g. caffeine 8-oxidation, omeprazole sulphoxidation, midazolam 1'-hydroxylation and midazolam 4-hydroxylation) of structurally unrelated compounds, including steroids, fatty acids, and xenobiot...
Gene Name:
CYP3A4
Uniprot ID:
P08684
Molecular Weight:
57342.67 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]

Transporters

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inducer
General Function:
Organic anion transmembrane transporter activity
Specific Function:
Mediates hepatobiliary excretion of numerous organic anions. May function as a cellular cisplatin transporter.
Gene Name:
ABCC2
Uniprot ID:
Q92887
Molecular Weight:
174205.64 Da
References
  1. Kauffmann HM, Pfannschmidt S, Zoller H, Benz A, Vorderstemann B, Webster JI, Schrenk D: Influence of redox-active compounds and PXR-activators on human MRP1 and MRP2 gene expression. Toxicology. 2002 Feb 28;171(2-3):137-46. [PubMed:11836020 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Xenobiotic-transporting atpase activity
Specific Function:
Energy-dependent efflux pump responsible for decreased drug accumulation in multidrug-resistant cells.
Gene Name:
ABCB1
Uniprot ID:
P08183
Molecular Weight:
141477.255 Da
References
  1. Hu XM, Hirano T, Oka K: Arsenic trioxide induces apoptosis equally in T lymphoblastoid leukemia MOLT-4 cells and P-gp-expressing daunorubicin-resistant MOLT-4 cells. Cancer Chemother Pharmacol. 2003 Feb;51(2):119-26. Epub 2002 Nov 20. [PubMed:12647012 ]
  2. Wei HL, Yao XJ, Li YN, Wang P, Zhao HS, Bai DC, Peng X, Ma LF: [Arsenic trioxide inhibits P-glycoprotein expression in multidrug-resistant human leukemia K562/ADM cell line that overexpresses mdr-1 gene and enhances their chemotherapeutic sensitivity]. Zhonghua Xue Ye Xue Za Zhi. 2003 Jan;24(1):28-31. [PubMed:12679007 ]
  3. Wei H, Su H, Bai D, Zhao H, Ge J, Wang B, Yao X, Ma L: Arsenic trioxide inhibits p-glycoprotein expression in multidrug-resistant human leukemia cells that overexpress the MDR1 gene. Chin Med J (Engl). 2003 Nov;116(11):1644-8. [PubMed:14642128 ]
  4. Kimura A, Ishida Y, Wada T, Yokoyama H, Mukaida N, Kondo T: MRP-1 expression levels determine strain-specific susceptibility to sodium arsenic-induced renal injury between C57BL/6 and BALB/c mice. Toxicol Appl Pharmacol. 2005 Feb 15;203(1):53-61. [PubMed:15694464 ]
  5. Cronin CJ, Mendel JE, Mukhtar S, Kim YM, Stirbl RC, Bruck J, Sternberg PW: An automated system for measuring parameters of nematode sinusoidal movement. BMC Genet. 2005 Feb 7;6:5. [PubMed:15698479 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on December 07, 2016 02:38